Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ alpha-1b Adrenergic Receptor Monoclonal Antibody (471802)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA524191
Description
This antibody stains human ADRA1B transfectants but not irrelevant transfectants. Reconstitute at 0.5 mg/mL in sterile PBS.
The alpha-1b adrenoceptor is an Adrenergic Receptor that causes contraction of smooth muscle cells and thereby controls vascular tone, blood pressure, and accelerates the development of atherosclerosis. Decreased alpha-1b adrenoceptor is associated with benign prostatic hyperplasia (BPH). This adrenergic receptor also acts as a proto-oncogene when transfected into cell lines where constitutive activation of the receptor induces neoplastic transformation. The alpha-1b adrenoceptor has been documented in adrenal, aorta, blood, various brain regions, eye, heart, kidney, liver, prostate, spinal cord, and spleen. ESTs have been isolated from kidney (normal and cancer) and lung carcinoma libraries.
Specifications
alpha-1b Adrenergic Receptor | |
Monoclonal | |
0.5 mg/mL | |
PBS with 5% trehalose and No Preservative | |
P35368 | |
Adra1b | |
NS0 mouse myeloma cell line transfected with human ADRA1B Met1-Phe520. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG2b |
Flow Cytometry | |
471802 | |
Unconjugated | |
Adra1b | |
[a]1b; ADA1B; ADRA1; ADRA1B; Adrenergic alpha 1B- receptor; adrenergic receptor, alpha 1b; adrenergic, alpha-1B-, receptor; adrenoceptor alpha 1B; alpha 1B-adrenoceptor; alpha 1B-adrenoreceptor; alpha-1B adrenergic receptor; Alpha-1B adrenoceptor; alpha-1B adrenoreceptor; alpha-1B-adrenergic receptor; alpha1B-adrenergic receptor; ALPHA1BAR | |
Mouse | |
Protein A/G | |
RUO | |
147 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction